[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Liapakis IE, Korkolis DP, Koutsoumbi A, Fida A, Kokkalis G, Vassilopoulos PP: Malignant hidradenoma: a report of two cases and review of the literature. Anticancer Res; 2006 May-Jun;26(3B):2217-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant hidradenoma: a report of two cases and review of the literature.
  • Clear cell hidradenoma is a lesion with histopathological features resembling those of eccrine poroma and eccrine spiradenoma.
  • The biological behavior of the tumor is aggressive, with local recurrences reported in more than 50% of the surgically-treated cases.
  • The first patient underwent wide excision with clear margins and axillary lymph node dissection and the second patient underwent wide excision of the primary lesion and bilateral inguinal node dissection due to palpable nodes.
  • Although he had received several chemotherapeutic agents, the disease had a relentless course and the patient succumbed two and a half years following surgery.
  • Additional resection is generally required, with at least 2-cm clear margins, since surgery is the only effective treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821590.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


2. Bollée G, Patey N, Cazajous G, Robert C, Goujon JM, Fakhouri F, Bruneval P, Noël LH, Knebelmann B: Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant; 2009 Feb;24(2):682-5
MedlinePlus Health Information. consumer health - Blood Clots.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Drugs targeting the VEGF pathway are associated with renal adverse events, including proteinuria, hypertension and thrombotic microangiopathy (TMA).
  • It was shown recently that sunitinib, a small molecule inhibiting several tyrosine kinase receptors, including VEGF receptors, can also induce proteinuria, hypertension and biological features of TMA. Case.
  • A 44-year-old woman with a history of malignant skin hidradenoma was started on sunitinib for refractory disease.
  • Renal function remained normal, and biological signs of TMA were absent.
  • This suggests that all anti-VEGF drugs may share a common risk for developing renal adverse events, including TMA.
  • The renin-angiotensin system blockers may be considered in patients with mild clinical manifestations and in the absence of therapeutic alternative to anti-VEGF drugs.
  • [MeSH-major] Indoles / adverse effects. Kidney / blood supply. Kidney / drug effects. Pyrroles / adverse effects. Thrombosis / chemically induced. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Adenoma, Sweat Gland / drug therapy. Adult. Antineoplastic Agents / adverse effects. Female. Humans. Protein Kinase Inhibitors / adverse effects. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nephrol Dial Transplant. 2009 Jun;24(6):2002-3 [19332867.001]
  • (PMID = 19054798.001).
  • [ISSN] 1460-2385
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib
  •  go-up   go-down


Advertisement
3. Piris A, Scopsi L, Clemente C, Cetti Serbelloni F, Mihm MC Jr, Hoang MP: Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas. Am J Dermatopathol; 2010 Aug;32(6):586-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor gene status by fluorescence in situ hybridization in malignant, atypical, and benign hidradenomas.
  • BACKGROUND: Epidermal growth factor receptor (EGFR) protein overexpression and gene amplification are important prognostic factors in various tumors and EGFR inhibitors are now available as promising chemotherapeutic agents.
  • There is little information in the literature regarding the EGFR protein and gene status in hidradenocarcinomas which has an aggressive biologic course characterized by repeated local recurrences and systemic metastasis.
  • We have previously reported EGFR protein overexpression in malignant, atypical, and benign hidradenomas and would like to further evaluate their gene status by fluorescence in situ hybridization.
  • METHODS: Fluorescence in situ hybridization by 2-color probe Vysis LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen Probe (Abbott Molecular) and EGFR immunostain (H11, Dakocytomation) were performed in 15 malignant, 15 atypical, and 7 benign hidradenomas.
  • Disomy is noted in the remaining 29 cases (9 hidradenocarcinomas, 15 atypical hidradenomas, and 5 benign hidradenomas).
  • EGFR overexpression was seen in 3/12 (25%) malignant hidradenomas, 7/15 (47%) atypical hidradenomas, and 3/5 (60%) benign hidradenomas; none of these cases demonstrated EGFR gene amplification.
  • CONCLUSIONS: Polysomy/trisomy is more frequently seen in hidradenocarcinoma than atypical and benign hidradenomas.
  • Lack of correlation between the protein expression and polysomy/gene amplification suggests that molecular mechanisms other than gene amplification play a role in EGFR overexpression in malignant, atypical, and benign hidradenomas.
  • [MeSH-major] Acrospiroma / pathology. Adenocarcinoma / secondary. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics. Sweat Gland Neoplasms / genetics. Sweat Gland Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Proliferation. Chromosome Aberrations. Gene Amplification. Humans. In Situ Hybridization, Fluorescence / methods. Lymph Nodes / pathology. Trisomy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534988.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down






Advertisement